Research programme: proto oncogene protein c-myc inhibitors - Peptomyc

Alternative Names: OMO-101; OMO-103; Omomyc-based cell penetrating peptides - Peptomyc; Omomyc-CPP

Latest Information Update: 11 May 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Peptomyc; Vall d-Hebron Research Institute
Class Antineoplastics; Peptides
Mechanism of Action Proto oncogene protein c-myc inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

11 May 2017 Research programme: proto oncogene protein c-myc inhibitors - Peptomyc is available for licensing as of 11 May 2017. http://www.peptomyc.com/
11 May 2017 Peptomyc plans a phase I/II trial in Glioblastoma (Peptomyc pipeline, May 2017)
01 Jan 2016 Preclinical trials in Cancer in Spain (Intranasal)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.